Search results
Showing 16 to 21 of 21 results for ruxolitinib
In development Reference number: GID-TA11760 Expected publication date: TBC
Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
This guidance has been updated and replaced by NICE technology appraisal guidance TA921.
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)
This guidance has been updated and replaced by NICE technology appraisal guidance 386.
Discontinued Reference number: GID-TA11007
This guidance has been updated and replaced by NICE technology appraisal guidance 1054.
First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people
For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo